Disc Medicine (IRON) Competitors $41.22 -4.55 (-9.94%) Closing price 04:00 PM EasternExtended Trading$41.23 +0.01 (+0.02%) As of 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRON vs. SRPT, RVMD, BBIO, LNTH, TGTX, LEGN, AXSM, TLX, BPMC, and KRYSShould you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Lantheus (LNTH), TG Therapeutics (TGTX), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Disc Medicine vs. Sarepta Therapeutics Revolution Medicines BridgeBio Pharma Lantheus TG Therapeutics Legend Biotech Axsome Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Krystal Biotech Disc Medicine (NASDAQ:IRON) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk. Do insiders & institutionals have more ownership in IRON or SRPT? 83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 4.2% of Disc Medicine shares are held by company insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is IRON or SRPT more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Disc Medicine's net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -25.24% -23.96% Sarepta Therapeutics 7.43%11.00%3.35% Does the media refer more to IRON or SRPT? In the previous week, Sarepta Therapeutics had 40 more articles in the media than Disc Medicine. MarketBeat recorded 42 mentions for Sarepta Therapeutics and 2 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 1.70 beat Sarepta Therapeutics' score of 0.46 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sarepta Therapeutics 14 Very Positive mention(s) 3 Positive mention(s) 16 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, IRON or SRPT? Disc Medicine has higher earnings, but lower revenue than Sarepta Therapeutics. Disc Medicine is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$76.43M-$3.99-10.37Sarepta Therapeutics$1.90B2.93-$535.98M$2.2825.15 Which has more volatility and risk, IRON or SRPT? Disc Medicine has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Does the MarketBeat Community believe in IRON or SRPT? Sarepta Therapeutics received 1411 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 86.57% of users gave Disc Medicine an outperform vote while only 75.03% of users gave Sarepta Therapeutics an outperform vote. CompanyUnderperformOutperformDisc MedicineOutperform Votes5886.57% Underperform Votes913.43%Sarepta TherapeuticsOutperform Votes146975.03% Underperform Votes48924.97% Do analysts rate IRON or SRPT? Disc Medicine currently has a consensus price target of $93.80, suggesting a potential upside of 126.80%. Sarepta Therapeutics has a consensus price target of $163.18, suggesting a potential upside of 184.52%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Sarepta Therapeutics 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83 SummarySarepta Therapeutics beats Disc Medicine on 13 of the 17 factors compared between the two stocks. Remove Ads Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRON vs. The Competition Export to ExcelMetricDisc MedicinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$6.43B$5.33B$7.13BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-10.476.8022.8917.40Price / SalesN/A188.30357.5184.53Price / CashN/A65.6738.1634.64Price / Book2.925.636.253.79Net Income-$76.43M$142.11M$3.21B$247.10M7 Day Performance-21.01%-11.37%-8.04%-7.61%1 Month Performance-25.27%-14.47%-2.99%-10.32%1 Year Performance40.20%-18.40%3.54%-7.75% Disc Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRONDisc Medicine3.0547 of 5 stars$41.22-9.9%$93.80+127.6%+50.1%$1.42BN/A-10.3630Positive NewsGap DownHigh Trading VolumeSRPTSarepta Therapeutics4.7604 of 5 stars$76.33+3.0%$167.41+119.3%-53.8%$7.41B$1.90B61.061,314Quiet Period ExpirationNews CoverageRVMDRevolution Medicines4.0645 of 5 stars$39.34+3.2%$66.31+68.6%+4.7%$7.31B$742,000.00-10.96250Analyst ForecastNews CoveragePositive NewsGap DownBBIOBridgeBio Pharma4.5459 of 5 stars$37.22+7.0%$52.90+42.1%+16.6%$7.08B$221.90M-13.06400Insider TradeGap DownHigh Trading VolumeLNTHLantheus4.2649 of 5 stars$99.44+1.8%$129.43+30.2%+64.2%$6.81B$1.53B16.55700Positive NewsGap DownTGTXTG Therapeutics2.7954 of 5 stars$42.61-0.9%$40.67-4.6%+171.9%$6.69B$329.00M-426.06290Positive NewsGap DownLEGNLegend Biotech2.4875 of 5 stars$36.33-1.7%$79.00+117.5%-41.7%$6.67B$627.24M-38.241,800Short Interest ↓News CoverageAXSMAxsome Therapeutics4.6266 of 5 stars$129.17+1.9%$167.36+29.6%+46.8%$6.30B$385.69M-21.56380Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$18.24+2.5%$22.00+20.6%N/A$6.14B$783.21M0.00N/ANews CoverageGap DownBPMCBlueprint Medicines2.6397 of 5 stars$95.27+7.4%$124.95+31.2%-5.6%$6.09B$508.82M-88.21640News CoveragePositive NewsKRYSKrystal Biotech4.7971 of 5 stars$194.44+3.9%$220.00+13.1%+0.1%$5.60B$290.52M65.03210Analyst RevisionNews CoveragePositive NewsGap Down Remove Ads Related Companies and Tools Related Companies Sarepta Therapeutics Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Lantheus Alternatives TG Therapeutics Alternatives Legend Biotech Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Blueprint Medicines Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRON) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
